Glipizide Extended Release Tablets

Not yet clear.

Glipizide

It is suitable for patients with mild to moderate type 2 diabetes who have not achieved satisfactory results with diet control and physical exercise for 2 to 3 months. The pancreatic beta cells of such diabetic patients must have a certain insulin secretion function, and have no acute complications (such as infection trauma, ketoacidosis, hyperosmolar coma, etc.), no pregnancy, and no serious chronic complications.

Oral. The dosage varies from person to person. The generally recommended dosage is 2.5-20 mg/day, taken 30 minutes before breakfast. If the daily dosage exceeds 15 mg, it is advisable to take it three times before meals in the morning, noon and evening. For those who have failed diet therapy alone: the starting dose is 2.5-5 mg per day, and the dosage is increased or decreased according to the blood sugar and urine sugar situation, increasing or decreasing by 2.5-5.0 mg each time. If the daily dosage exceeds 15 mg, take it 2-3 times before meals. For those who have used other oral sulfonylurea hypoglycemic drugs: stop taking other sulfonylurea drugs for 3 days, and start taking this product after rechecking blood sugar. Gradually increase the dosage from 5 mg until the ideal therapeutic effect is achieved. The maximum daily dose does not exceed 30 mg.

1. The most common symptoms are gastrointestinal symptoms (such as nausea, upper abdominal distension) and headache, which can be relieved by reducing the dose. 2. Some patients may experience skin allergies. 3. Hypoglycemia is occasionally seen, especially in the elderly and weak, those who are overactive, those who eat irregularly, drink alcohol or have liver damage. 4. There are also occasional reports of reversible changes in the hematopoietic system, such as granulocytopenia, thrombocytopenia, etc.

1. Patients who are allergic to this product and sulfonamides. 2. Patients with type 1 diabetes who have been diagnosed. 3. Patients with type 2 diabetes accompanied by stressful conditions such as ketoacidosis, coma, severe burns, infection, trauma, and major surgery. 4. Patients with liver and kidney dysfunction. 5. Patients with leukopenia. 6. Patients with adrenal insufficiency.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Pregnancy: Pregnancy category C: Rat reproduction studies found mild embryotoxicity at all dose levels (5-50 mg/kg), which is similar to the toxic effects observed in other sulfonylureas such as tolbutamide and tolazamide. Precautions for the elderly: Use with caution in the elderly.

Not yet clear.

Keep away from light and store in sealed container.

5 mg

0 month